Tag Archives: investors

BIO Investor Forum Company Snapshot: AM-Pharma

AM Pharma

The BIO Investor Forum will be taking place this October in San Francisco for its 12th annual event. So far this year, the hot topic is, of course, the hot market. Out of all the therapeutic US companies that have had an IPO in 2013, 71% of them have attended the BIO Investor Forum. The program for the event will thus feature two great panels about the recent IPO activity, in addition to other therapeutic workshops Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Biotech Hall of Fame: Interview with Biotech’s First Investment Banker

Biotech Hall of Fame

Earlier this week, I had the opportunity to discuss biotech’s storied history with Fred Frank, one of the industry’s greatest luminaries, on what we can learn from the past to help shape the future. Fred Frank, formerly Vice Chairman of both Lehman Brothers Inc. and Peter J. Solomon Company, recently became Vice Chairman of Burrill & Company and Chairman of Burrill Securities, the broker dealer arm of Burrill & Company. He was the first life Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , ,

The Year Ahead for Business Development Events

BIO China

2013 is officially here (insert stale End-of-the-World joke). And as such, planning has been in full effect for BIO events. Here’s a recap of what’s coming up in the next few months. BIO’s in San Fran for JPM As a BIO member service, companies can schedule private meeting space for free during JP Morgan. This year, meetings will take place at The Palace Hotel, on the 5th floor. You can also find Celia, Dave, Kirsten Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , ,

Data Exclusivity Protects Innovators and Assures Investors

medical_research_thumb

Biotechnology companies must have some certainty that they can protect their investment in the development of new breakthrough therapies for a substantial period of time. This protection helps companies secure much-needed venture capital funding, which is the lifeblood of the industry. A failure to include substantial data exclusivity would undermine incentives to invest in biomedical innovation and thus would slow progress in the development of breakthrough therapies to improve the health and lives of patients Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

It Takes a Village: The New Pharma-VC Model for Biotech Investing

bif-hall

High-profile funding collaborations between pharmaceutical companies and traditional venture capital funds have made headlines in recent months, pooling resources and expertise in an attempt to source and develop the most successful drugs. BIO Executive Vice President Alan Eisenberg moderated It Takes a Village: The New Pharma-VC Model for Biotech Investing, a panel discussion about these new funding models, during the opening plenary session at the 2012 BIO Investor Forum. In the past, venture capital could Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,